首页 | 本学科首页   官方微博 | 高级检索  
     

冠状动脉介入治疗对冠心病患者血浆单核细胞趋化因子1和基质金属蛋白酶9的影响
引用本文:李琴,刘丽军,信栓力,常超,刘东燕,崔雪霞,张书丽,李雅琪,代艳君,张芙娴. 冠状动脉介入治疗对冠心病患者血浆单核细胞趋化因子1和基质金属蛋白酶9的影响[J]. 中国综合临床, 2014, 0(7): 698-700
作者姓名:李琴  刘丽军  信栓力  常超  刘东燕  崔雪霞  张书丽  李雅琪  代艳君  张芙娴
作者单位:河北省邯郸市第一医院心内科,056002
摘    要:目的:探讨冠心病患者行冠状动脉介入(PCI)治疗前后血浆单核细胞趋化因子1(MCP-1)及基质金属蛋白酶9(MMP-9)的改变。方法连续入选经冠状动脉造影证实单支病变的冠心病患者50例(PCI 组),冠状动脉正常者30例(对照组),检测对照组造影前后和 PCI 组介入前后血浆 MCP-1和MMP-1,比较两组间的差异。结果(1)PCI 组患者介入后血浆 MCP-1为(19.87±5.31)ng/ L,介入术前为(15.71±5.23)ng/ L,差异有统计学意义(t =3.95,P <0.01);对照组冠状动脉造影术后 MCP-1为(13.78±5.58)ng/ L,术前为(12.42±5.39)ng/ L,差异无统计学意义(P =0.34)。(2)PCI 组患者介入术后血浆 MMP-9为(22.69±5.97)mg/ L,术前为(19.52±5.72)mg/ L,差异有统计学意义(t =2.71,P<0.01);对照组冠状动脉造影术后 MMP-9为(17.53±5.51)mg/ L,造影术前为(16.69±5.42)mg/ L,差异无统计学意义(P =0.55)。结论 PCI 促进冠心病患者血浆 MCP-1及 MMP-1水平的升高,是否为介入治疗术后支架内再狭窄的重要机制之一尚待进一步考证。

关 键 词:冠心病  冠状动脉介入术  单核细胞趋化因子1  基质金属蛋白酶9

Effect of plasma monocyte chemotactic factor-1 protein and matrix metalloproteinase-9 of patients with coronary artery disease following percutaneous coronary interventional procedures therapy
Li Qin,Liu Lijun,Xin Shuanli,Chang Chao,Liu Dongyan,Cui Xuexia,Zhang Shuli,Li Yaqi,Dai Yanjun,Zhang Fuxian. Effect of plasma monocyte chemotactic factor-1 protein and matrix metalloproteinase-9 of patients with coronary artery disease following percutaneous coronary interventional procedures therapy[J]. Clinical Medicine of China, 2014, 0(7): 698-700
Authors:Li Qin  Liu Lijun  Xin Shuanli  Chang Chao  Liu Dongyan  Cui Xuexia  Zhang Shuli  Li Yaqi  Dai Yanjun  Zhang Fuxian
Affiliation:(Cardiology Department, the First Hospital of Handan , Handan 056002, China)
Abstract:Objective To explore the change of monocyte chemotactic factor-1 protein(MCP-1)and matrix metalloproteinase-9( MMP-9)of patients with coronary artery disease( CAD)following percutaneous coronary interventional( PCI). Methods Fifty patients underwent PCI procedures for CAD compromising a single coronary artery were selected as PCI group and 30 healthy individuals with normal findings by coronary angiography were selected as the control group. Plasma MCP-1 and MMP-9 were measured in all the subjects. Results The plasma MCP-1 level of patients with CAD after PCI was(19. 87 ± 5. 31)ng/ L,higher than that before operation((15. 71 ± 5. 23)ng/ L,t = 3. 95,P 〈 0. 01). Whereas in the control group,the MCP-1 level after coronary angiography was(13. 78 ± 5. 58)ng/ L,which was as same as that before operation (12. 42 ± 5. 39 ng/ L,P = 0. 34). Plasma MMP-9 level in the CAD patients after PCI procedures was(22. 69 ± 5. 97)mg/ L,higher than that before operation((19. 52 ± 5. 72)mg/ L,t = 2. 71,P 〈 0. 01). There was no significant difference in term of plasma MMP-9 level in control group befor and after operation((17. 53 ± 5. 51) mg/ L vs.(16. 69 ± 5. 42)mg/ L,P = 0. 55). Conclusion Plasma MCP-1 and MMP-9 increase in CAD patients following PCI procedures. But their roles in the vascular restenosis following the procedures need further investigation.
Keywords:Coronary artery disease  Percutaneous coronary interventional  Monocyte chemotactic factor-1 protein  Matrix metalloproteinase-9
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号